Crescent Biopharma (CBIO) Profit After Tax Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 33.04% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.60% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -154.28% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.53% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 47.10% |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | -30.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.99% |
| Dec 31, 2025 | -31.51% |
| Sep 30, 2025 | -42.37% |
| Jun 30, 2025 | -17.98% |
| Mar 31, 2025 | -1.11% |
| Dec 31, 2024 | -0.84% |
| Sep 30, 2024 | 46.66% |
| Jun 30, 2024 | 11.16% |
| Mar 31, 2024 | 9.06% |
| Dec 31, 2023 | 16.44% |
| Sep 30, 2023 | 12.47% |
| Jun 30, 2023 | 16.29% |
| Mar 31, 2023 | -10.57% |
| Dec 31, 2022 | 11.39% |
| Sep 30, 2022 | 13.68% |
| Jun 30, 2022 | 5.72% |
| Mar 31, 2022 | -1.33% |
| Dec 31, 2021 | -7.80% |
| Sep 30, 2021 | -14.40% |
| Jun 30, 2021 | -8.48% |
| Mar 31, 2021 | -7.43% |
| Dec 31, 2020 | -18.90% |
| Sep 30, 2020 | -19.96% |
| Jun 30, 2020 | -20.03% |
| Mar 31, 2020 | 1.14% |
| Dec 31, 2019 | -20.92% |
| Sep 30, 2019 | -19.05% |
| Jun 30, 2019 | -25.17% |
| Mar 31, 2019 | -23.07% |
| Dec 31, 2018 | -16.12% |
| Sep 30, 2018 | -17.32% |
| Jun 30, 2018 | -45.58% |
| Mar 31, 2018 | -17.43% |
| Dec 31, 2017 | -7.78% |
| Sep 30, 2017 | -6.31% |
| Jun 30, 2017 | -44.53% |
| Mar 31, 2017 | -15.84% |
| Dec 31, 2016 | -29.14% |
| Sep 30, 2016 | -28.51% |
| Jun 30, 2016 | -32.16% |
| Mar 31, 2016 | -164.17% |